Gabapentin is not a standard treatment for Parkinson’s disease, and current medical guidelines don’t recommend it for core Parkinson’s symptoms. One small double-blind trial did find improvements in motor scores, but the evidence is too limited to support routine use. Where gabapentin may play a more practical role is in managing certain non-motor problems that commonly accompany Parkinson’s, particularly sleep disruption, restless legs syndrome, and neuropathic pain.
What One Trial Found for Motor Symptoms
A double-blind, placebo-controlled crossover trial published in The American Journal of Medicine tested gabapentin against placebo in patients with parkinsonism. Patients taking gabapentin showed statistically significant improvement in their total scores on the Unified Parkinson’s Disease Rating Scale (the standard tool for measuring disease severity), with a p-value of 0.0005. The researchers concluded that gabapentin improved rigidity, bradykinesia (slowness of movement), and tremor. Even when the effects on tremor were removed from the analysis, rigidity and bradykinesia still improved.
That sounds promising, but context matters. This was a single small study, and no large follow-up trials have confirmed the results. The subscores for daily living activities and motor examination improved but didn’t reach statistical significance on their own. Tremor improvement showed up on clinical rating scales but not on a more objective electrical measurement of muscle activity. No major movement disorder organization currently lists gabapentin as a recommended treatment for Parkinson’s motor symptoms.
How Gabapentin Works in the Brain
Parkinson’s disease is driven by the loss of dopamine-producing brain cells, but gabapentin doesn’t affect dopamine directly. Instead, it increases levels of GABA, one of the brain’s main calming chemicals. A study using high-powered brain imaging found that a single 900 mg dose of gabapentin raised brain GABA concentrations by an average of 55.7%. Interestingly, people who started with lower baseline GABA levels saw the biggest increases. Gabapentin did not significantly change levels of glutamate, the brain’s primary excitatory chemical.
This GABA-boosting effect likely explains why gabapentin can help with sleep, pain, and restless legs. But it also explains why it’s not a substitute for dopamine-based therapies like levodopa or dopamine agonists, which target the underlying chemical deficit in Parkinson’s.
Sleep Problems and Restless Legs
Sleep disruption is one of the most common non-motor complaints in Parkinson’s, affecting the majority of patients at some point. Gabapentin has significant evidence supporting its use for insomnia, sleep fragmentation, and restless legs syndrome in this population. It increases slow-wave sleep (the deepest, most restorative sleep stage) and improves overall sleep efficiency.
For restless legs syndrome specifically, gabapentin has been shown in clinical studies to reduce the involuntary leg movements that fragment sleep. One crossover study found that an average dose of about 1,855 mg improved restless legs scores over six weeks, along with improvements in total sleep time and sleep quality. An open-label study found gabapentin and ropinirole (a dopamine agonist commonly used for restless legs) were similarly effective and well tolerated.
One trade-off: gabapentin can cause daytime drowsiness in some people, which is already a problem for many Parkinson’s patients. Current evidence supports both positive and negative effects on excessive daytime sleepiness, so this is something to watch for.
Neuropathic Pain in Parkinson’s
Pain affects a large proportion of people with Parkinson’s, and neuropathic pain (burning, tingling, or shooting sensations caused by nerve dysfunction) is particularly common. Gabapentin is widely used for neuropathic pain in general, and clinicians frequently prescribe it for Parkinson’s patients experiencing this type of pain. However, the 2024 Brazilian Academy of Neurology guidelines note that no randomized controlled trials have specifically studied gabapentin for pain in Parkinson’s. The guidelines classify the evidence as “insufficient” (level U) to formally recommend it for this purpose, while also acknowledging it is frequently administered.
Levodopa-Induced Dyskinesia
Some researchers have explored whether gabapentin could reduce the involuntary writhing movements (dyskinesia) that develop in many patients after years of levodopa therapy. A double-blind crossover study tested gabapentin at doses up to 2,400 mg per day in patients with complicated Parkinson’s disease to see if it changed the motor response to levodopa. The results were not strong enough to establish gabapentin as a useful add-on for dyskinesia, and this approach has not gained traction in clinical practice.
Safety Concerns for Parkinson’s Patients
Gabapentin carries several risks that are especially relevant for people with Parkinson’s. The most frequently reported side effects are dizziness, drowsiness, fatigue, and confusion. For people already dealing with balance problems and a higher fall risk from Parkinson’s itself, these effects can be compounding.
Cognitive effects deserve particular attention. A retrospective study of cognitively normal older adults (age 65 and older) found that starting gabapentin was associated with measurable cognitive decline over the following two years. A large Taiwanese database study found that gabapentin or pregabalin use was associated with a 45% increased risk of developing dementia compared to matched non-users, and the risk climbed with higher cumulative doses. Since cognitive decline is already a concern in Parkinson’s disease, this association is worth discussing with a prescriber.
Perhaps the most counterintuitive risk: gabapentin itself has been linked to parkinsonism. A pharmacoepidemiologic study analyzing over 5.6 million adverse event reports found that both gabapentin and pregabalin were associated with more than double the expected reporting rate for parkinsonian symptoms. This raises the possibility that in some patients, gabapentin could actually worsen the movement symptoms it’s being used to treat. The Brazilian guidelines specifically note that patients taking gabapentin for pain should be monitored for worsening motor symptoms.
Where Gabapentin Fits in Parkinson’s Care
Gabapentin is not a Parkinson’s treatment in the way that levodopa or dopamine agonists are. It doesn’t address the dopamine loss driving the disease, and the single trial showing motor symptom improvement hasn’t been replicated at scale. No major guideline recommends it as a primary therapy for Parkinson’s motor symptoms.
Its practical value is as a supporting medication for specific non-motor symptoms. If you’re dealing with fragmented sleep, restless legs at night, or neuropathic pain alongside your Parkinson’s, gabapentin is one of the tools a neurologist might consider. It’s most useful when one medication can address multiple overlapping complaints, like a patient who has both restless legs and insomnia. But the cognitive risks and the potential to worsen motor symptoms mean it’s not a casual addition to a medication regimen, particularly for older patients or those already experiencing memory difficulties.